// App-Quantinova.ai

979 : Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials

Researchers

Presenter

  • Jorge Sanchez-Guerrero

Principal Investigators

  • Susan Manzi

  • Naoto Yokogawa

  • Joerg Wenzel

  • Josephine C. Ocran-Appiah

  • Munther Khamashta

  • Julia H N Harris

  • Bernie Rubin

  • Norma Lynn Fox

  • Roger A Levy

  • Victoria Werth

Medical Centers

  • Allegheny Health Network, Lupus Center of Excellence, Wexford, PA

  • University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada

  • Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan

  • University of Bonn, Department of Dermatology and Allergy, Bonn, Germany

  • GlaxoSmithKline, Clinical Science Immunology, Rockville, MD

  • GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates

  • GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom

  • GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC

  • GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA

  • Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN

Locations

  • United States

  • Canada

  • Japan

  • Germany

  • United Arab Emirates

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved